The aim of the presentation is to show how Selvita became multinational biotech company



Cracow University of Economics

Agata Kubajka

Gabriela Kukla

Magdalena Kurcz

Establishing of the company

First Selvita's laboratory and grant for SEL120

IPO on the Warsaw Stock Exchange

2014

Plan of building Selvita's own centre of R&D

Beginning of clinical examination of SEL24

2007

2008

2010

2012

2015

2016

2017

2019

Purchase of molecule SEL24

Grant for developing anticancer therapy

Appearing on western market - USA & Britain

Giving SEL120 to the human for the first time

INNOVATIVE PROJECTS

SEL120:

Selvita's second largest project for the treatment of AML and other rare oncological diseases worth 130 million PLN

September 2019 - first clinical research (first patient)

SEL24

First of the most advanced project currently investigated for the treatment of Acute Myeloid

Leukemia

March 2017 — first-in-human entered

POZNAŃ

Contract with the Adam Mickiewicz
University in Poznań for renting
laboratories in the buildings of the
Wielkopolska Center of Advanced
Technologies

SAN FRANCISCO

Selvita Inc. with head office in Cambridge, Massachusetts - renewal of cooperation contract from 2016 with University of California in San Francisco (UCSF) for next 3 years.

UNIVERSITIES



BOSTON

Greater Boston Area the first foreign office in the neighborhood of Massachusetts Institute of Technology, Harvard University and medical centers

CAMBRIDGE

Cambridge cooperation from 5th of May 2015 is focused on supporting and developing business relationships with local partners

Selvita's competitive advantage is a result of it's activity in highly innovative area. Biotechnology segment is advanced technology and being it's leader is an incredible success for small start-up from Cracow.